...
首页> 外文期刊>癌と化学療法 >Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy
【24h】

Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy

机译:乙型肝炎病毒携带者中急性型CD 8阳性成人T细胞白血病的发展-拉米夫定联合化疗可能具有治疗作用

获取原文
获取原文并翻译 | 示例
           

摘要

Cases of adult T-cell leukemia (ATL) with aberrant phenotypes have a very poor prognosis. We report the development of acute type, CD 8 positive ATL in a carrier of hepatitis B virus (HBV). The patient was treated with a combination of lamivudine and chemotherapy and consequently had longer-term survival than those reported previously. A 64-year-old(corrected 65-year-old) man was referred to our hospital in January 2002 because of ascites and abdominal tumor. He was positive for anti-HTLV-1 antibody and HBV surface antigen. Generalized computed tomography demonstrated bilateral pleural effusion, abdominal mass, and massive ascites. Cytological examination of ascitis revealed numerous atypical lymphoid cells,which were positive for CD 2, CD 5, CD 8, and CD 25. Monoclonal integration of HTLV-1 provirus was detected by Southern blot analysis on DNA extracted from lymphoid cells. A diagnosis of acute type, CD 8 positive ATL was made. Lamivudine was administered for prevention of chemotherapy induced HBV reactivation. Subsequently, he was treated with 6 cycles of CHOP and went into remission. He maintained clinical remission during a follow-up of 13 months and then relapsed. Further salvage therapies were provided with a transient effect. He died of sepsis in February 2004. The overall survival time of this patient was 25 months. It is possible that lamivudine combined with chemotherapy may have had a therapeutic effect on ATL in this case.
机译:具有异常表型的成人T细胞白血病(ATL)病例预后很差。我们报告了乙型肝炎病毒(HBV)携带者中CD 8阳性ATL急性型的发展。该患者接受拉米夫定和化学疗法的联合治疗,因此比先前报道的患者具有更长的生存期。 2002年1月,一名64岁(校正后的65岁)男子因腹水和腹部肿瘤被转诊到我院。他的抗HTLV-1抗体和HBV表面抗原呈阳性。全身计算机断层扫描显示双侧胸腔积液,腹部肿块和大量腹水。囊炎的细胞学检查显示有许多非典型淋巴样细胞,它们对CD 2,CD 5,CD 8和CD 25呈阳性。通过对从淋巴样细胞提取的DNA进行Southern印迹分析,检测到HTLV-1前病毒的单克隆整合。诊断为急性型,CD 8阳性ATL。服用拉米夫定可预防化疗引起的HBV激活。随后,他接受了6个CHOP周期的治疗,并获得缓解。他在13个月的随访期间保持了临床缓解,然后又复发了。进一步的挽救疗法具有短暂的作用。他于2004年2月死于败血症。该患者的总生存时间为25个月。在这种情况下,拉米夫定联合化疗可能对ATL有治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号